National Asset Management, Inc. Checkpoint Therapeutics, Inc. Transaction History

National Asset Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.02 - $10.6 $55,080 - $572,400	54,000 Added 52.68%	156,500 $163,000
Q2 2022 Aug 12, 2022	BUY	$0.97 - $1.77 $5,432 - $9,912	5,600 Added 5.78%	102,500 $106,000
Q1 2022 May 02, 2022	BUY	$1.53 - $3.25 $612 - $1,300	400 Added 0.41%	96,900 $172,000
Q4 2021 Jan 28, 2022	SELL	$2.68 - $4.46 $60,300 - $100,350	-22,500 Reduced 18.91%	96,500 $301,000
Q3 2021 Nov 16, 2021	BUY	$2.5 - $3.53 $7,500 - $10,590	3,000 Added 2.59%	119,000 $393,000
Q2 2021 Aug 10, 2021	BUY	$2.36 - $3.2 $59,000 - $80,000	25,000 Added 27.47%	116,000 $343,000
Q1 2021 May 13, 2021	BUY	$2.6 - $4.16 $144,300 - $230,880	55,500 Added 156.34%	91,000 $286,000
Q4 2020 Feb 04, 2021	BUY	$2.19 - $2.96 $13,140 - $17,760	6,000 Added 20.34%	35,500 $95,000
Q3 2020 Nov 09, 2020	BUY	$1.62 - $4.24 $47,790 - $125,080	29,500 New	29,500 $80,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $302M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on National Asset Management, Inc. with notifications on news.